Search

Displaying results 4931 - 4940 of 10000 in total
  1. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication

  2. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide. … Tetraethylammonium is an experimental drug with no approved indication or marketed formulation.

  3. Drug

    JNJ-54175446

    go.drugbank.com/drugs/DB15358
    Investigational

    JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid

  4. Drug

    Nizofenone

    go.drugbank.com/drugs/DB13546
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Acriflavine

    go.drugbank.com/drugs/DB13373
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Mitonafide

    go.drugbank.com/drugs/DB19492
    Experimental

    Mitonafide is a small molecule drug. Mitonafide has a monoisotopic molecular weight of 313.11 Da.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds. … This is followed by purification and expansion of the cells in vitro.

  8. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  9. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  10. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.